About this trial
Texture and Colour Enhancement Imaging (TXI) improves texture, brightness, and colour in white-light endoscopy to highlight subtle tissue differences. Now available through the EVIS X1 system, early evidence suggests potential value in IBD. Studies show that TXI may help predict ulcerative colitis relapse and performs comparably to dye chromoendoscopy in detecting lesions, though no randomised data exist for dysplasia detection in IBD surveillance. We therefore propose a randomised paired study comparing TXI with high-definition white-light endoscopy for dysplasia detection in IBD surveillance.
Eligibility criteria
Qualifiers
Patients >16 with inflammatory bowel disease undergoing surveillance colonoscopy.
Patients with Crohn's (L2/L3 Montreal classification) with >50% colonic involvement OR
Patients with ulcerative colitis with Extensive or left sided disease (E3 or E2 Montreal classification) for at least 8 years or a diagnosis of Primary sclerosing cholangitis concomitant with IBD.
Disqualifiers
Disease duration <8 years unless a diagnosis of PSC
Incomplete colonoscopy
BBPS <6 or <2 in any segment
MES ≥2 or any variable of the SES-CD is ≥2 or any stenosis for >10cm segment (above the rectum)
Trial design
Treatments tested in this trial
- TXI